Dr. Jack Jacobs received his Ph.D. in Molecular Biology from the Washington University School of Medicine, St. Louis where he worked in the lab of Ralph Bradshaw, PhD which was the first lab to isolate and work on FGF-1. After graduating, he worked at Merck & Co. where he started the Department of Biological Chemistry. Later, he joined Mr. Montano at CardioVascular BioTherapeutics as their Chief Scientific Officer where he oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease and diabetic foot ulcers. He also supervised all manufacturing activities of FGF-1 for use in the clinical studies.